Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML

ABSTRACTObjectives We performed a feasibility study of an FDA-approved commercial ddPCR assay to measure BCR::ABL1 in CML patients treated using TKI therapy.Methods Assay performance of standard RQ-PCR and commercially available FDA-approved ddPCR were compared to measure BCR::ABL1 p210 transcripts...

Full description

Bibliographic Details
Main Authors: Adcharee Kongruang, Nittaya Limsuwanachot, Sutada Magmuang, Prapatsorn Areesirisuk, Pimjai Niparuck, Teerapong Siriboonpiputtana, Budsaba Rerkamnuaychoke
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Hematology
Subjects:
BCR::ABL1 transcript
MRD
real-time quantitative PCR (RQ-PCR)
droplet digital PCR (ddPCR)
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2023.2256199

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2023.2256199

Similar Items